期刊文献+

卡马西平严重皮肤不良反应发病机制的研究进展 被引量:20

原文传递
导出
摘要 目的综述近年来国内外对卡马西平严重皮肤不良反应发病机制的研究进展,为卡马西平不良反应研究和临床安全合理应用卡马西平及芳香族抗癫痫药物提供参考。方法查阅并结合国内外相关文献,对卡马西平严重皮肤不良反应的临床特征、可能的发病机制等方面进行综述。结果与结论卡马西平严重皮肤不良反应发病机制复杂,与代谢、免疫和遗传等因素有关。
出处 《中国药学杂志》 CAS CSCD 北大核心 2012年第18期1462-1464,共3页 Chinese Pharmaceutical Journal
基金 国家自然科学基金面上项目(30973597) 辽宁省科学技术计划项目(2009225020)
  • 相关文献

参考文献33

  • 1BU H Z,KANG P,DEESE A J,et al. Human in vitro glutathionyl and protein adducts of carbamazepine-10,11 -epoxide, a stable and pharmacologically active metabohte of carbamazepine [ J ]. Drug Metab Dispos,2005 ,33(12 ) : 1920-1924.
  • 2AIHARA M. Pharmacogenetics of cutaneous adverse drug reactions [J]. J Dermatol,2011,38(3) : 246-254.
  • 3ZACCARA G, FRANCIOTYA D, PERUCCA E. Idiosyncratic ad- verse reactions to antiepileptic drugs [ J ]. Epilepsi, 2007,48 (7) : 1223-1244.
  • 4CHUNG W H, HUNG S I. Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis [ J ]. A1- lergol lnt,2010,59(4) : 325-332.
  • 5TERAKI Y ,SHIBUYA M ,IZAKI S. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clini- cal and laboratory features with drug-induced hypersensitivity syn- drome, despite differences in cutaneous presentations [ J ]. Clin Exp Dermato1,2010,35 (7) : 723-728.
  • 6MANSUR A T, PEKCAN YASAR S, GOKTAY F. Anticonvulsant hypersensitivity syndrome : Clinical and laboratory features [ J ]. lnt J Dermatol,2008,47 ( 11 ) : 1184-1189.
  • 7PEREIRA DE SILVA N,PIQUIONI P,KOCHEN S,et al. Risk fac- tors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs [ J ]. Eur J Clin Pharmaco1,2011,67 (5) :463-470.
  • 8SON C H, LEE C U, ROH M S, et al. Acute generalized exanthem- atous pustulosis as a manifestation of carbamazepine hypersensitivi- ty syndrome. [J]. J Investig Allergol Clin Immunol,2008 ,18( 6 ) : 461-464.
  • 9LU W, UETRECHT J P. Peroxidase-mediated bioactivation of hy- droxylated metabolites of carbamazepine and phenytoin [ J ]. Drug Metab Dispos ,2008,36 (8) : 1624-1636.
  • 10NOOR F,NIKLAS J,MULLER-VIEIRA U,et al. An integrated ap- proach to improved toxicity prediction for the safety assessment dur- ing preclinical drug development using Hep G2 cells [ J ]. Toxicol Appl Pharmacol, 2009,237(2) : 221-231.

二级参考文献13

  • 1Valeyrie-Allanore L, Sassolas B, Roujeau JC. Druginduced skin, nail and hair disorders[J]. Drug Saf, 2007, 30(11):1011-1030.
  • 2Pullen H, Wright N, Murdoch JM. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis[J]. Lancet, 1967, 2(7527): 1176-1178.
  • 3Levy M. The combined effect of viruses and drugs in drug-induced diseases[J]. Med Hypotheses, 1984, 14(3): 293-296.
  • 4Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of durg-induced hypersensitivity syndrome [J]. Br J Dermatol, 2007,157(5):934-940.
  • 5Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection[J]. Clin Rev Allergy Immunol, 2007,33(1-2):124-133.
  • 6Teraki Y, Murota H, Izaki S. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6[J]. Arch Dermatol, 2008, 144(2):232-235.
  • 7Tavakoli NP, Nattanmai S, Hull R, et al. Detection and typing of human herpesvirus 6 by molecular methods in specimens from patients diagnosed with encephalitis or meningitis[J]. J Clin Microbiol, 2007, 45(12):3972-3978.
  • 8Wolff K, Goldsmith LA, Katz SI, et al. Fitzpatrick's dermatology in general medicine [M]. 7th ed. New York: McGraw-Hill, 2008:355-362.
  • 9Salahuddin SZ, Ablashi DV, Markham PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders[J]. Science, 1986, 234(4776):596-601.
  • 10Kondo K, Kondo T, Okuno T, et al. Latent human herpesvirus 6 infection of human monocytes/macrophages[J]. J Gen Virol, 1991, 72(Pt 6):1401-1408.

共引文献3

同被引文献162

引证文献20

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部